AstraZeneca: receives Breakthrough Therapy designation
(CercleFinance.com) - AstraZeneca announces that datopotamab deruxtecan (Dato-DXd), co-developed with Daiichi Sankyo, has received Breakthrough Therapy (BTD) designation in the US for the treatment of locally advanced or metastatic EGFR-mutated non-small cell lung cancer (NSCLC), after progression on EGFR tyrosine kinase inhibitor and platinum-based chemotherapy.
Based on data from Phase II and Phase III trials, this designation reflects the significant clinical improvement observed.
Results supporting this application were presented at the ESMO Asia 2024 congress.
Copyright (c) 2024 CercleFinance.com. All rights reserved.
Based on data from Phase II and Phase III trials, this designation reflects the significant clinical improvement observed.
Results supporting this application were presented at the ESMO Asia 2024 congress.
Copyright (c) 2024 CercleFinance.com. All rights reserved.